Independent register of U.S. FDA drug recalls · updated Nov 2, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Sep 25, 2026 (38 days ago)

Sermorelin

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of process control

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Sermorelin, 1 mg/mL, 10 ml vial, Sterile injectable solution, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.

Drug: Sermorelin

Recalling firm
Houston Rx LLC
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0041-2027 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Sermorelin recalls

See all
Class II · Moderate risk

Sermorelin Acetate 1 mg/mL

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding D-0781-2022

Other recalls by Houston Rx LLC

All 2026 recalls